The American Heart Association has recognized the McKelvey School of Engineering’s Jonathan Silva with its Established Investigator Award. The five-year $400,000 award will support his work into precision medicine for patients with irregular heartbeat.
Washington University’s Jonathan Silva and Jeanne Nerbonne led a team that found that two drugs sometimes prescribed to treat arrhythmias affect heart atria and ventricles differently depending on the molecular composition of the sodium channels expressed.
Jonathan Silva, a biomedical engineer in the McKelvey School of Engineering at Washington University in St. Louis, has developed the first computational model that shows the molecular groundwork of a popular drug’s effectiveness in a variety of ways.
An international team, including faculty from the School of Engineering & Applied Science at Washington University in St. Louis, has used genetic phenotype to determine which patients would benefit the most from a commonly used drug treatment.
Irregular heartbeat — or arrhythmia — can have sudden and often fatal consequences. A biomedical engineering team at Washington University in St. Louis examining molecular behavior in cardiac tissue recently made a surprising discovery that could someday impact treatment of the life-threatening condition.